Peter Mohr
Impact in
- Oncology top 0.1%
- Cancer Immunotherapy and Biomarkers
- Cutaneous Melanoma Detection and Management
- Molecular Biology top 1%
- Melanoma and MAPK Pathways
Papers in
- Oncology 115
- Cutaneous Melanoma Detection and Management 74
- Cancer Immunotherapy and Biomarkers 48
- Polyomavirus and related diseases 8
-
- Melanoma and MAPK Pathways 32
- Co-authors
- Dirk Schadendorf (25 shared papers)Axel Hauschild (29 shared papers)Claus Garbe (20 shared papers)Jochen Sven Utikal (9 shared papers)Reinhard Dummer (5 shared papers)Peter Hersey (3 shared papers)Uwe Trefzer (8 shared papers)Jessica C. Hassel (9 shared papers)
- Journals
- European Journal of Cancer (26 papers)Annals of Oncology (22 papers)JDDG Journal der Deutschen Dermatologischen Gesellschaft (18 papers)Cancers (9 papers)Melanoma Research (8 papers)
- Partner nations
- GermanyUnited StatesUnited Kingdom
In The Last Decade
Peter Mohr
164 papers receiving 16.1k citations
Peter Mohr's Hit Papers
Peers
Comparison fields: 5 of 114
- Oncology 8.8k
- Molecular Biology 4.8k
- Cancer Research 765
- Ophthalmology 458
- Pulmonary and Respiratory Medicine 1.3k
Countries citing papers authored by Peter Mohr
This map shows the geographic impact of Peter Mohr's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Mohr with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Mohr more than expected).
Fields of papers citing papers by Peter Mohr
This network shows the impact of papers produced by Peter Mohr. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Mohr. The network helps show where Peter Mohr may publish in the future.
Co-authors
The 25 scholars most cited alongside Peter Mohr, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 175 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial Hit paper breakdown → | 2015 | 2303 |
| 2 | Genomic correlates of response to CTLA-4 blockade in metastatic melanoma Hit paper breakdown → | 2015 | 2293 |
| 3 | Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma Hit paper breakdown → | 2012 | 1821 |
| 4 | Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma Hit paper breakdown → | 2014 | 1559 |
| 5 | Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group Hit paper breakdown → | 2012 | 1224 |
| 6 | Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial Hit paper breakdown → | 2015 | 1137 |
| 7 | Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study Hit paper breakdown → | 2017 | 539 |
| 8 | Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis Hit paper breakdown → | 2017 | 500 |
| 9 | 2013 | 414 | |
| 10 | 2004 | 394 | |
| 11 | Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial Hit paper breakdown → | 2021 | 300 |
| 12 | 2015 | 213 | |
| 13 | 2020 | 199 | |
| 14 | 2014 | 173 | |
| 15 | 2023 | 137 | |
| 16 | 2003 | 128 | |
| 17 | 2009 | 119 | |
| 18 | 2010 | 118 | |
| 19 | 2022 | 112 | |
| 20 | 2011 | 107 |
About Peter Mohr
Peter Mohr is a scholar working on Oncology, Molecular Biology, Epidemiology, Dermatology and Ophthalmology, having authored 175 papers that have together received 16.4k indexed citations. Recurring topics across this work include Cutaneous Melanoma Detection and Management (74 papers), Cancer Immunotherapy and Biomarkers (48 papers), Melanoma and MAPK Pathways (32 papers), Nonmelanoma Skin Cancer Studies (17 papers), Polyomavirus and related diseases (8 papers), Brain Metastases and Treatment (6 papers), Ocular Oncology and Treatments (5 papers) and Soft tissue tumor case studies (5 papers). The work is most often cited by research in Oncology (8.8k citations), Molecular Biology (4.8k citations), Cancer Research (765 citations), Ophthalmology (458 citations) and Pulmonary and Respiratory Medicine (1.3k citations). Peter Mohr has collaborated with scholars based in Germany, United States and United Kingdom. Frequent co-authors include Dirk Schadendorf, Axel Hauschild, Claus Garbe, Jochen Sven Utikal, Reinhard Dummer, Peter Hersey, Uwe Trefzer, Jessica C. Hassel, Caroline Robert and Piotr Lukasz Rutkowski. Their work appears in journals such as European Journal of Cancer, Annals of Oncology, JDDG Journal der Deutschen Dermatologischen Gesellschaft, Cancers and Melanoma Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.